accellta ltd

Accellta develops cultured dairy fat as a high-quality alternative to milk fat, with similar taste, texture, and nutrition. Its unique technology enables efficient, industrial-scale production without animal dependence.

Accellta develops customized processes and media for the manufacturing of stem cells for drug discovery companies screening new drug candidates or performing functional or toxicology studies using human differentiated cells or organoids and. for clinical stage Cell therapy and Regenerative medicine companies. Accellta's technologies are the result of over 15 years of pioneering research and development at the Stem Cell Center in the Rappaport Faculty of Medicine at the Technion - Israel institute of Technology. Accellta's unique 3D suspension culture technologies enable mass production and differentiation of stem cells in dynamic bioreactors without adherence surfaces and xeno-free and serum-free media. The technologies have been extensively studied in pluripotent stem cells (PSCs), both embryonic (ESCs) and induced (iPSCs) from a variety of sources. The technologies are estimated to reduce the manufacturing cost of PSCs, progenitors and fully differentiated cells by over a tenfold and to shorten the duration by more than a third. MAXELLS™ - The Power of Suspension Culturing. Maxells, Accellta's novel solution for industrialization of embryonic and induced pluripotent stem cell culturing, is based on dynamic culturing of stem cells in suspension without microcarriers or feeder cells. Maxells allows uniform cell growth and improved cell differentiation and delivers unprecedented scalability and quality. SINGLES™ - Superior Uniformity and Optimal Scalability. "Singles" is a breakthrough technology that offers a simple and effective way to culture pluripotent stem cells as single-cells in suspension, serving as a platform for genetic manipulation of the cells and providing enhanced uniformity and purity. Accellta offers protocols and custom solutions for directed differentiation of pluripotent stem cells in suspension to representative cells of the three embryonic germ layers to progenitor lines, such as neural progenitors, or mesenchymal stem cells, and to fully differentiated cells, such as cardiomyocytes and motor neurons.

Regenerative medicine companies Cell Therapy companies Pharmaceutical companies CMOs CROs Stem Cell Research Labs

Michal Amit - CEO & CTO, Co-Founder

Michal Amit - CEO & CTO, Co-Founder

Yael Garfinkel - CFO